First Half Results 2021
Sep 10, 2021
Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update
Jun 04, 2021
KEDRAB® is now the first and only HRIG available in the U.S. to be clinically studied in children
First Quarter 2021 Results
Jun 01, 2021
Kedrion maintains its revenues and outperformed management’s expectations.
Annual General Meeting of Shareholders 2021
Apr 30, 2021
Offering of New Notes
Apr 26, 2021
Not for release, publication or distribution, directly or indirectly, in the United States of America (or for the account or benefit of “U.S. persons” as defined in Regulation S under the U.S. Securities Act of 1933), Canada, Australia or Japan or in any other jurisdiction where to do so would be unlawful. PRESS RELEASE –